Investor Relations

Website Notice Block

Corporate Profile

MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

MediWound Reports First Quarter 2024 Financial Results and Provides Company Update

May 29, 2024

 NexoBrid ® interest surges; $5 million in Q1 2024 revenue, with $24 million forecast for the year Manufacturing facility on target for completion by mid-2024 EscharEx ® Phase III study to launch 2H 2024 Company set to join Russell 3000® Index Conference call today, May 29 at 8:30am Eastern Time

MediWound to Report First Quarter 2024 Financial Results

May 22, 2024

Conference Call and Webcast Scheduled for Wednesday, May 29th at 8:30 am Eastern Time YAVNE, Israel, May 22, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced that the Company will release its